Sugi Predict

Sugi Predict / Compounds / SCHEMBL5074148

SCHEMBL5074148

SCHEMBL5074148

N[C@@H](CC(=O)OC(=O)[C@@H](N)CS)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.56
▸ SLC7A11 Q9UPY5 1/20 0.56
▸ GRIK1 P39086 7/20 0.41
▸ GRIK2 Q13002 4/20 0.41
▸ GRM1 Q13255 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ GRIA4 P48058 3/20 0.39
▸ GRIK3 Q13003 3/20 0.39
▸ GRIK5 Q16478 3/20 0.39
▸ SLC7A5 Q01650 1/20 0.38
▸ ENPEP Q07075 2/20 0.36
▸ GGT1 P19440 4/20 0.35
▸ SLC1A1 P43005 4/20 0.35
▸ SLC1A3 P43003 2/20 0.34
▸ SLC1A2 P43004 2/20 0.34
▸ GRIA2 P42262 2/20 0.34
▸ GRIA1 P42261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1235817 0.88 PTGS1 (0.43) PTGS1SLC7A11ENPEP
SCHEMBL666315 0.88 PTGS1 (0.43) PTGS1SLC7A11ENPEP
SCHEMBL9701317 0.86 GRIK1 (0.45) PTGS1SLC7A11GRIK1GRIK2GRM1
SCHEMBL17222477 0.86 GRIK1 (0.45) PTGS1SLC7A11GRIK1GRIK2GRM1
SCHEMBL27392924 0.85 PTGS1 (0.47) PTGS1SLC7A11GRIK1GRIK2GRIA4
SCHEMBL16466602 0.82 SLC1A1 (0.45) PTGS1SLC7A11GRIK1GRIK2GRM1
SCHEMBL344252 0.81 PTGS1 (0.52) PTGS1SLC7A11GRIK1GRIK2GRM1
SCHEMBL6239265 0.81 GRIK1 (0.41) PTGS1SLC7A11GRIK1GRIK2GRM1
SCHEMBL9763734 0.79 PTGS1 (0.46) PTGS1SLC7A11ENPEP
SCHEMBL2873837 0.79 PTGS1 (0.46) PTGS1SLC7A11ENPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002433-A1 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2024-01-04 — — US disclosed
US-11634455-B2 Amino diacids containing peptide modifiers CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2023-04-25 — — US disclosed
EP-3038658-B1 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S A (GR) 2020-11-04 — — EP disclosed
EP-3725801-A2 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS Chemical & Biopharmaceutical Laboratories of Patras S.A. (GR) 2020-10-21 — — EP disclosed
EP-3086664-B1 METHOD OF PREPARING NUTRITIONALLY FORTIFIED YEAST HILLS PET NUTRITION INC (US) 2020-07-15 — — EP disclosed
US-10561162-B2 Method of preparing palatability enhancer COLGATE-PALMOLIVE COMPANY (US) 2020-02-18 — — US disclosed
US-20190177362-A1 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2019-06-13 — — US disclosed
US-20160326484-A1 HIGH NUTRIENT YEAST HILL'S PET NUTRITION, INC. (US) 2016-11-10 — — US disclosed
EP-3086664-A1 HIGH NUTRIENT YEAST Hill's Pet Nutrition, Inc. (US) 2016-11-02 — — EP disclosed
US-20160302458-A1 Method of Preparing Palatability Enhancer HILLS PET NUTRITION INC (US) 2016-10-20 — — US disclosed
US-20080308243-A1 Cationic Crosslinked Starch Containing Compositions and Use Thereof CARGILL, INCORPORATED (US) 2008-12-18 — — US disclosed
EP-1882011-A1 CATIONIC CROSSLINKED STARCH CONTAINING COMPOSITIONS AND USE THEREOF Cargill, Incorporated (US) 2008-01-30 — — EP disclosed
WO-2006124869-A1 CATIONIC CROSSLINKED STARCH CONTAINING COMPOSITIONS AND USE THEREOF CARGILL, INCORPORATED (US) 2006-11-23 — — WO disclosed
US-20060254738-A1 Cationic crosslinked starch containing compositions and use thereof CARGILL, INCORPORATED 2006-11-16 — — US disclosed
US-6103487-A DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS MERCK & CO., INC. (US) 2000-08-15 — — US disclosed
US-6048531-A Immunogenic composites capable of stimulating production of anti-peptide antibodies, pharmaceutical compositions employing these composites and methods of selectively inducing production of anti-peptide antibodies ALBANY MEDICAL COLLEGE (US) 2000-04-11 — — US disclosed
US-6037149-A NUCLEOTIDE SEQUENCE CODING HUMAN INTERLEUKIN-9; FOR THE DIAGNOSIS OF SENSITIVITY TO ALLERGY AND ASTHMA MAGAININ PHARMACEUTICALS INC. (US) 2000-03-14 — — US disclosed
US-5998407-A ANTICANCER, ANTITUMOR AGENT MERCK & CO., INC. (US) 1999-12-07 — — US disclosed
EP-0575304-B1 Sulfonamide peroxycarboxylic acids AKZO NOBEL NV (NL) 1996-09-25 — — EP disclosed
EP-0575304-A1 Sulfonamide peroxycarboxylic acids Akzo Nobel N.V. (NL) 1993-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177362-A1 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS PTMS, PEPD, VIP PTGS1 1754/4885SLC7A11 732/4885GRIK1 1200/4885
US-11634455-B2 Amino diacids containing peptide modifiers PTMS, PEPD, VIP PTGS1 1754/4885SLC7A11 732/4885GRIK1 1200/4885
US-20240002433-A1 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS PTMS, PEPD, NGLY1 PTGS1 1745/4885SLC7A11 727/4885GRIK1 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.